Research and Markets has announced the addition of the "Seizures - Pipeline Insights, 2017" report to their offering.

Seizures - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Seizures.

The This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Seizures.

This report also assesses the Seizures therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Key Topics Covered:

  1. Seizures Overview
  2. Seizures Disease Associated
  3. Seizures Pipeline Therapeutics
  4. Seizures Therapeutics under Development by Companies
  5. Seizures Filed and Phase III Products
  6. Seizures Phase II Products
  7. Seizures Phase I and IND Filed Products
  8. Seizures Discovery and Pre-Clinical Stage Products
  9. Drug Candidate Profiles
  10. Seizures - Therapeutics Assessment
  11. Seizures - Discontinued Products
  12. Seizures - Dormant Products
  13. Companies Involved in Therapeutics Development for Seizures
  14. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/bdzdk5/seizures

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Related Topics: Central Nervous System Drugs